Sistema de Salut de Catalunya
Institut Català de la Salut
[Mondejar-Lopez P] Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain. Department of Surgery, Paediatrics, Obstetrics and Genecology, Biomedical Research Institute of Murcia (IMIB), Universidad de Murcia, Murcia, Spain. [Moreno-Galarraga L] Department of Pediatrics, Complejo Hospitalario de Navarra, Servicio Navarro de Salud, Pamplona, Spain. IdiSNA (Instituto de Investigación Sanitaria de Navarra), Navarra Institute for Health Research, Pamplona, Spain. [de Manuel-Gomez C] Pediatric Pulmonology Department and Cystic Fibrosis Unit, Hospital La Paz Institute for Health Research—IdiPAZ, Madrid, Spain. [Blitz-Castro E] Pediatric Pulmonology Department and Cystic Fibrosis Unit, Hospital Ramón y Cajal & Institute for Health Research—IRYCIS, Madrid, Spain. [Bravo-Lopez M, Gartner S] Unitat de Pneumologia Pediàtrica i Fibrosi Quística, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-11-08T09:31:49Z
2023-11-08T09:31:49Z
2023-11
COVID-19; Pediatria; Vacunació
COVID-19; Pediatría; Vacunación
COVID-19; Pediatrics; Vaccination
Introduction The association between viral infections and pulmonary exacerbations in children with cystic fibrosis (cwCF) is well established. However, the question of whether cwCF are at a higher risk of COVID-19 or its adverse consequences remains controversial. Methods We conducted an observational, multicenter, cross-sectional study of cwCF infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) between March 2020 and June 2022, (first to sixth COVID-19 pandemic waves) in Spain. The study aimed to describe patients' basal characteristics, SARS-CoV-2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves. Results During study time, 351 SARS-CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0–17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (sixth wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid-19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). Infection occurring along the sixth wave was the only independent risk factor for being symptomatic. Just eight cwCF needed hospital admission. No multisystem inflammatory syndrome, persisting symptoms, long-term sequelae, or deaths were reported. Conclusions Spanish current data indicate that cwCF do not experience higher risks of SARS-CoV-2 infection nor worse health outcomes or sequelae. Changes in patients' basal characteristics, clinical courses, and outcomes were detected across waves. While the pandemic continues, a worldwide monitoring of COVID-19 in pediatric CF patients is needed.
Article
Published version
English
Infants; Fibrosi quística; COVID-19 (Malaltia); DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; DISEASES::Respiratory Tract Diseases::Lung Diseases::Cystic Fibrosis; NAMED GROUPS::Persons::Age Groups::Child; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::fibrosis quística; DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño
Wiley
Pediatric Pulmonology;58(11)
https://doi.org/10.1002/ppul.26644
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3439]
